New immunotherapy against cancer wins the Kaye Innovation Award

June 08, 2016

The importance of the body's immune system in protecting against the creation of cancerous tumors has been known for a long time. But despite the existence of a competent immune system, some individuals develop tumors, in part because tumors have ways to evade destructive immunity or induce immune-suppression.

A major goal of cancer immunotherapy is to generate, induce or augment an anti-tumor immune response. In recent years, studies found that even after a tumor is formed the immune system is able to destroy it.

Dr. Pinchas Tsukerman studied the interaction between cancer cells and the key cells of the immune system that perform surveillance and elimination of tumor cells, called Natural Killer (NK) cells. On the basis of this research, he developed novel products that can boost the immune activity to eliminate cancer growths.

Dr. Tsukerman conducted the research as a PhD student at the Lautenberg Center for Immunology and Cancer Research, at the Institute for Medical Research Israel-Canada (IMRIC). IMRIC is a research institute within the Faculty of Medicine at the Hebrew University of Jerusalem.

His discovery, which earned him the prestigious Kaye Innovation Award, was made at the laboratory of Prof. Ofer Mandelboim (a 2015 Kaye award winner -- see http://new.huji.ac.il/en/article/26933) in collaboration with the laboratory of Prof. Stipan Jonjic from the University of Rijeka in Croatia.

NK cell activity is controlled by a balance of signals delivered by inhibitory and activating NK cell receptors. There are several activating NK cell receptors that recognize various ligands (surface molecules expressed by damaged or transformed cells), including tumor specific ligands.

"Our products are blocking monoclonal antibodies (mAbs) that target and block one of the inhibitory receptors as well as the ligand of the inhibitory receptor. Each of these mAbs is able to induce potent immune responses," Tsukerman said.

Additionally, these mAbs can act synergistically with existing immunotherapies, such as anti-PD1, anti-PD1L and anti-CTLA4.

"We thus have high hopes for using these novel anti-tumor mAbs to better treat cancer in the future," said Tsukerman.

The Hebrew University, through its technology transfer company, Yissum, holds patent applications protecting the new method, and it is now in the process of signing an agreement with a company for further development and commercialization.

Tsukerman's innovation was one of five which earned the Kaye Innovation Award during the 79th annual meeting of the Hebrew University Board of Governors.

Tsukerman was previously awarded the Rector's Award for excellent students in his first year at Hebrew University, and the Bester Award and the IMRIC award for excellence in cancer research.

The Kaye Awards have been given annually since 1994. Isaac Kaye from the United Kingdom, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff and students of The Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society.
-end-
The Hebrew University of Jerusalem is Israel's leading academic and research institution, producing one-third of all civilian research in Israel. For more information, visit http://new.huji.ac.il/en.

The Hebrew University of Jerusalem

Related Immune System Articles from Brightsurf:

How the immune system remembers viruses
For a person to acquire immunity to a disease, T cells must develop into memory cells after contact with the pathogen.

How does the immune system develop in the first days of life?
Researchers highlight the anti-inflammatory response taking place after birth and designed to shield the newborn from infection.

Memory training for the immune system
The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen.

Immune system may have another job -- combatting depression
An inflammatory autoimmune response within the central nervous system similar to one linked to neurodegenerative diseases such as multiple sclerosis (MS) has also been found in the spinal fluid of healthy people, according to a new Yale-led study comparing immune system cells in the spinal fluid of MS patients and healthy subjects.

COVID-19: Immune system derails
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.

Immune cell steroids help tumours suppress the immune system, offering new drug targets
Tumours found to evade the immune system by telling immune cells to produce immunosuppressive steroids.

Immune system -- Knocked off balance
Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune diseases and allergies.

Too much salt weakens the immune system
A high-salt diet is not only bad for one's blood pressure, but also for the immune system.

Parkinson's and the immune system
Mutations in the Parkin gene are a common cause of hereditary forms of Parkinson's disease.

How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.

Read More: Immune System News and Immune System Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.